S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Price, News & Analysis

$4.35
+0.02 (+0.46%)
(As of 03/1/2024 ET)
Today's Range
$4.28
$4.38
50-Day Range
$4.30
$5.49
52-Week Range
$2.42
$6.29
Volume
41,465 shs
Average Volume
72,054 shs
Market Capitalization
$185.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Harvard Bioscience MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
60.9% Upside
$7.00 Price Target
Short Interest
Healthy
1.85% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.07
Upright™ Environmental Score
News Sentiment
-0.07mentions of Harvard Bioscience in the last 14 days
Based on 27 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
128.57%
From $0.07 to $0.16 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.62 out of 5 stars

Computer And Technology Sector

72nd out of 598 stocks

Analytical Instruments Industry

5th out of 26 stocks


HBIO stock logo

About Harvard Bioscience Stock (NASDAQ:HBIO)

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. The company was founded in 1901 and is based in Holliston, Massachusetts.

HBIO Stock Price History

HBIO Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
See More Headlines
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/02/2024
Next Earnings (Confirmed)
3/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
436
Year Founded
1901

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+60.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-9,520,000.00
Pretax Margin
-2.08%

Debt

Sales & Book Value

Annual Sales
$113.33 million
Cash Flow
$0.22 per share
Book Value
$1.73 per share

Miscellaneous

Free Float
40,041,000
Market Cap
$185.70 million
Optionable
Optionable
Beta
1.43

Social Links

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report














HBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Harvard Bioscience stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" HBIO shares.
View HBIO analyst ratings
or view top-rated stocks.

What is Harvard Bioscience's stock price target for 2024?

1 equities research analysts have issued twelve-month price objectives for Harvard Bioscience's stock. Their HBIO share price targets range from $7.00 to $7.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price.
View analysts price targets for HBIO
or view top-rated stocks among Wall Street analysts.

How have HBIO shares performed in 2024?

Harvard Bioscience's stock was trading at $5.35 at the start of the year. Since then, HBIO stock has decreased by 18.7% and is now trading at $4.35.
View the best growth stocks for 2024 here
.

When is Harvard Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our HBIO earnings forecast
.

How can I listen to Harvard Bioscience's earnings call?

Harvard Bioscience will be holding an earnings conference call on Thursday, March 7th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Harvard Bioscience's earnings last quarter?

Harvard Bioscience, Inc. (NASDAQ:HBIO) announced its quarterly earnings data on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.06. The medical instruments supplier earned $29.66 million during the quarter, compared to analyst estimates of $28.10 million. Harvard Bioscience had a positive trailing twelve-month return on equity of 3.42% and a negative net margin of 2.90%. During the same quarter last year, the business posted $0.01 EPS.

What other stocks do shareholders of Harvard Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD).

Who are Harvard Bioscience's major shareholders?

Harvard Bioscience's stock is owned by many different institutional and retail investors. Top institutional shareholders include AMH Equity Ltd (5.07%), Vanguard Group Inc. (4.93%), Dimensional Fund Advisors LP (4.51%), Granahan Investment Management LLC (4.32%), Meros Investment Management LP (1.92%) and Acuitas Investments LLC (0.76%). Insiders that own company stock include Alan I Edrick, Bertrand Loy, James W Green and James W Green.
View institutional ownership trends
.

How do I buy shares of Harvard Bioscience?

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Harvard Bioscience have any subsidiaries?
The following companies are subsidiares of Harvard Bioscience: Data Sciences International.
Read More
This page (NASDAQ:HBIO) was last updated on 3/2/2024 by MarketBeat.com Staff